Bringing point-of-care diagnostics closer to Queensland patients

Clinical innovation in point-of-care diagnostics is changing how quickly health professionals can identify disease, assess risk, and begin treatment. Instead of sending every specimen to a central laboratory, clinicians can use compact testing platforms at a bedside, community clinic, ambulance station, pharmacy, or rural health facility.

These tools range from rapid antigen tests and blood gas analysers to molecular assays, handheld ultrasound, digital microscopy, and wearable biosensors. Their value depends on more than speed. A result must be accurate, understandable, connected to clinical workflows, and supported by a clear plan for follow-up.

For Queensland health services, implementation is strongest when researchers, clinicians, consumers, and technology developers work together. The health translation network provides a relevant model for connecting evidence with care across hospitals, universities, research institutes, and communities.

Why rapid testing matters at the point of care

Central laboratory testing remains essential for complex analysis and quality assurance, yet distance and processing time can delay decisions. A rapid result can help clinicians determine whether a patient needs antibiotics, isolation, urgent referral, additional imaging, or immediate escalation.

In emergency and urgent care settings, near-patient testing may support earlier recognition of sepsis, cardiac injury, respiratory infection, pregnancy complications, or metabolic instability. In chronic disease management, portable tests can give patients and care teams immediate information about glucose, coagulation, kidney function, or inflammatory markers.

The benefit is especially significant in rural and remote areas, where transport logistics and limited laboratory access can widen health inequities. Point-of-care technology cannot solve every access problem, but it can reduce avoidable delays when it is selected for a genuine clinical need.

From prototype to dependable clinical tool

A promising diagnostic device must pass through several stages before it becomes routine care. Researchers need to establish analytical validity: whether the test measures the intended marker accurately and consistently. Clinical validation then examines how well the result identifies a condition or predicts an outcome in the population that will use it.

Implementation research addresses a different question: can the test work reliably in the real environment? A device designed for a laboratory may perform poorly in a busy emergency department if staff training, maintenance, infection control, connectivity, or consumable supply have not been considered.

The strongest programmes define success before deployment. Measures may include time to treatment, avoidable transfers, diagnostic accuracy, patient experience, staff workload, and health outcomes. These measures help distinguish a useful innovation from a device that simply produces results more quickly.

Designing around people and clinical workflows

Technology should fit the way patients and professionals actually move through care. A test that requires multiple manual steps may create errors during a crowded shift. A result that appears in a separate software system may be overlooked. A device that is difficult to use for people with limited vision, language barriers, or reduced dexterity may deepen inequity.

Co-design can identify these risks early. Patients, carers, nurses, allied health professionals, doctors, Aboriginal and Torres Strait Islander health workers, laboratory scientists, and information technology teams each see different parts of the diagnostic journey. Their input can shape consent processes, result communication, escalation pathways, and training materials.

Equity should be assessed alongside performance. Developers and health services need to consider whether an assay performs differently across age groups, pregnancy status, skin tones, comorbidities, disability, or cultural and linguistic communities. Accessibility, affordability, privacy, and the availability of confirmatory testing all influence whether innovation improves outcomes in practice.

Connecting research, services, and governance

Translation succeeds when evidence can move between discovery, evaluation, and clinical use. A partnership model that connects hospitals and universities helps align research priorities with service needs and creates routes for clinicians to test ideas in authentic care environments.

Governance is central to responsible deployment. Projects may require ethics review, privacy assessment, pathology oversight, procurement review, cybersecurity controls, and regulatory approval. Data generated by connected devices should have clear ownership, access rules, retention periods, and safeguards against inappropriate use.

Health services also need a sustainability plan. This includes budgeting for reagents, calibration, software updates, equipment replacement, accreditation, waste disposal, and staff time. A pilot can appear successful while relying on exceptional effort from a small group. Sustainable scale requires defined accountability and routine monitoring.

Building digital and diagnostic capability

Modern point-of-care testing increasingly depends on interoperable digital systems. Results should be captured accurately in the electronic medical record, linked to the correct patient, and made visible to the people responsible for action. Automated alerts can support timely care, but poorly designed alerts may increase fatigue and unnecessary intervention.

Workforce education should cover specimen collection, device operation, quality control, troubleshooting, interpretation, and communication with patients. Competency must be maintained when staff rotate between departments or when testing expands beyond laboratory professionals.

Clinical innovation programmes can strengthen capability by pairing technical education with practical evaluation. Training teams to ask whether a test changes management helps keep attention on patient benefit rather than novelty. Publications, shared protocols, communities of practice, and cross-service learning can make successful methods easier to adapt.

Priorities for responsible implementation

A disciplined approach can help Queensland services select technologies that are clinically meaningful and operationally realistic.

• Define the unmet clinical need before selecting a device or assay.
• Validate accuracy in the population and setting where testing will occur.
• Include patients, carers, frontline staff, laboratory experts, and digital teams in design decisions.
• Build quality assurance, data governance, training, and maintenance into the business case.
• Track patient outcomes, equity effects, workflow impact, and total cost after launch.

Evaluation should continue after adoption. Usage patterns may change, new variants may affect assay performance, and staff may develop workarounds that were not visible during the pilot. Regular review allows services to improve protocols, retire ineffective tools, and direct investment toward technologies with measurable value.

Turning faster results into better care

Point-of-care diagnostics are most powerful when they shorten the path from uncertainty to appropriate action. The goal is not simply to place a testing device closer to a patient. It is to build a reliable clinical pathway in which the result is trusted, understood, recorded, and connected to treatment or referral.

Researchers and health services can accelerate this work by sharing evidence, developing practical partnerships, and evaluating innovations against outcomes that matter to patients and communities. Explore collaborative opportunities, research resources, and health translation activity through Brisbane Diamantina Health Partners to help move promising diagnostic ideas into safer, more equitable care.